# IGFBP5 is released by senescent cells and is internalized by healthy cells, promoting their senescence through interaction with retinoic receptors

## TL;DR

This paper shows that IGFBP5, released by aging cells, causes nearby healthy cells to age by interacting with a specific protein, suggesting it could be a target for treating age-related diseases and cancer.

## Contribution

The paper identifies IGFBP5 as a novel SASP factor that promotes senescence via RARα interaction and caveolae-mediated internalization.

## Key findings

- IGFBP5 is released by senescent cells and induces senescence in healthy cells.
- IGFBP5 interacts with RARα and is internalized via caveolae to exert pro-senescence effects.
- Elevated IGFBP5 levels were observed in patients under CT-induced stress, linking it to organismal aging.

## Abstract

Cells that are exposed to harmful genetic damage, either from internal or external sources, may undergo senescence if they are unable to repair their DNA. Senescence, characterized by a state of irreversible growth arrest, can spread to neighboring cells through a process known as the senescence-associated secretory phenotype (SASP). This phenomenon contributes to both aging and the development of cancer. The SASP comprises a variety of factors that regulate numerous functions, including the induction of secondary senescence, modulation of immune system activity, remodeling of the extracellular matrix, alteration of tissue structure, and promotion of cancer progression. Identifying key factors within the SASP is crucial for understanding the underlying mechanisms of senescence and developing effective strategies to counteract cellular senescence. Our research has specifically focused on investigating the role of IGFBP5, a component of the SASP observed in various experimental models and conditions.

Through our studies, we have demonstrated that IGFBP5 actively contributes to promoting senescence and can induce senescence in neighboring cells. We have gained valuable insights into the mechanisms through which IGFBP5 exerts its pro-senescence effects. These mechanisms include its release following genotoxic stress, involvement in signaling pathways mediated by reactive oxygen species and prostaglandins, internalization via specialized structures called caveolae, and interaction with a specific protein known as RARα. By uncovering these mechanisms, we have advanced our understanding of the intricate role of IGFBP5 in the senescence process. The significance of IGFBP5 as a pro-aging factor stems from an in vivo study we conducted on patients undergoing Computer Tomography analysis. In these patients, we observed an elevation in circulating IGFBP5 levels in response to radiation-induced organismal stress.

Globally, our findings highlight the potential of IGFBP5 as a promising therapeutic target for age-related diseases and cancer.

The online version contains supplementary material available at 10.1186/s12964-024-01469-1.